EUVIMEDEUVIMED entdecken
FallberichtOpen Access

First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report

N A Mazerkina, S K Gorelyshev, A N Savateev, N A Strebkova, A L Kalinin

Problems of Endocrinology · 2024

DOI: 10.14341/probl13446 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Problems of Endocrinology, 2024. Verfasst von N A Mazerkina und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Center for Neurosurgery named after Academician N.N. Burdenko. Hauptthemen laut MEDLINE: Craniopharyngioma, Aromatase Inhibitors, Pituitary Neoplasms, Human Growth Hormone. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed. As a result of treatment, GH deficiency and secondary hypothyroidism developed. At age 9 years, signs of puberty appeared. Growth rate remained satisfactory until the age of 14 years. At the age of 14 growth rate slowed down, which was the reason for appointment. Upon examination, the bone age was 16 years and the projected final height without therapy was 162 cm. Given the poor growth prognosis, IA anastrozole in combination with GH was prescribed. During two years of therapy the growth gain amounted to 12.5 cm. This observation demonstrates that normal growth rates in patients with CP do not indicate preserved somatotropic function of the pituitary gland. With preserved sexual function, early or premature puberty may be observed. In such cases, IA can be prescribed in addition to GH — these are medications that inhibit the closure of growth. GH therapy in combination with IA is highly effective and safe in patients with GH deficiency after treatment of KF during puberty and allows to achieve good growth parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniopharyngiomaAromatase InhibitorsPituitary NeoplasmsHuman Growth HormoneGrowth DisordersNitrilesTriazolesHumansMaleAdolescentAnastrozolePrognosisDrug Therapy, CombinationTreatment Outcome

Substanzen

Aromatase InhibitorsHuman Growth HormoneAnastrozoleNitrilesTriazoles

Autor:innen und Institutionen

  • National Medical Research Center for Neurosurgery named after Academician N.N. Burdenko.
  • Gamma knife Centre.
  • Endocrinology Research Centre.

Zitieren

APA

Mazerkina, N. A., Gorelyshev, S. K., Savateev, A. N., Strebkova, N. A., & Kalinin, A. L. (2024). First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report. Problems of Endocrinology. https://doi.org/10.14341/probl13446

Vancouver

Mazerkina NA, Gorelyshev SK, Savateev AN, Strebkova NA, Kalinin AL. First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report. Problems of Endocrinology. 2024. doi:10.14341/probl13446

BibTeX
@article{Mazerkina2024,
  author = {Mazerkina, N A and Gorelyshev, S K and Savateev, A N and Strebkova, N A and Kalinin, A L},
  title = {First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report},
  journal = {Problems of Endocrinology},
  year = {2024},
  doi = {10.14341/probl13446}
}
Kostenlos starten →